Genmab A/S (NASDAQ:GMAB – Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.12, reports. Genmab A/S had a return on equity of 15.02% and a net margin of 19.08%.The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.11 billion.
Here are the key takeaways from Genmab A/S’s conference call:
- Genmab raised its 2026 guidance, now expecting revenue of DKK 4.3–4.5 billion and operating profit of DKK 1.1–1.4 billion. Revenue growth at the midpoint is projected at 19%, while operating expenses rise only 2%, highlighting expected operating leverage.
- First-half proprietary-product sales increased 37% to DKK 396 million, led by EPKINLY sales growth of 48% to DKK 312 million. Management cited accelerating U.S. community adoption, broader site activation, and strong uptake of the second-line follicular lymphoma regimen.
- Genmab reported statistically significant, clinically meaningful progression-free-survival results from the phase III EPCORE DLBCL-2 study and received European approval for EPKINLY plus lenalidomide and rituximab in second-line follicular lymphoma.
- Petosemtamab is being expanded into two global phase III colorectal cancer trials—frontline and second-line—in combination with chemotherapy. Management also expects frontline head-and-neck data in the fourth quarter and is positioning the asset as a potential multi-indication growth driver.
- Several major catalysts are expected in the coming quarters, including Rina-S phase II and III ovarian-cancer data and frontline EPKINLY data in the fourth quarter, while petosemtamab’s second- or third-line head-and-neck readout is now expected in the first quarter of 2027. Overall-survival data for the EPKINLY DLBCL study remain immature, and outcomes for these late-stage programs are still subject to clinical and regulatory uncertainty.
Genmab A/S Stock Up 4.8%
NASDAQ GMAB traded up $1.42 during trading hours on Friday, hitting $31.25. 3,507,361 shares of the company traded hands, compared to its average volume of 2,111,998. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. The business’s 50-day moving average is $27.31 and its 200-day moving average is $28.01. The stock has a market capitalization of $19.49 billion, a price-to-earnings ratio of 24.61, a P/E/G ratio of 1.87 and a beta of 0.83. Genmab A/S has a twelve month low of $21.00 and a twelve month high of $35.43.
Hedge Funds Weigh In On Genmab A/S
Wall Street Analysts Forecast Growth
GMAB has been the subject of several research analyst reports. Guggenheim upped their price target on shares of Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings upgraded Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, July 28th. New Street Research set a $43.00 price target on Genmab A/S in a report on Wednesday, July 22nd. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. Finally, BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.50.
Read Our Latest Research Report on GMAB
Genmab A/S News Summary
Here are the key news stories impacting Genmab A/S this week:
- Positive Sentiment: Royalty income lifted the outlook. Genmab’s drug-royalty revenue strengthened expectations for the business and was identified as a key reason the stock advanced. Genmab Stock Rises as Drug Royalties Lift Outlook
- Positive Sentiment: Q2 earnings exceeded expectations. Genmab reported EPS of $0.54, topping the $0.37 consensus estimate, while revenue of $1.16 billion surpassed expectations of $1.12 billion. The earnings beat reinforces the company’s profitability and operating momentum. Genmab Quarterly Earnings Results
- Positive Sentiment: Guggenheim raised its price target. The firm increased its target for GMAB from $40 to $42 and assigned a “Buy” rating, implying substantial upside from the stock’s recent trading level. Guggenheim Price Target Report
- Neutral Sentiment: Full-year revenue guidance is broadly in line with analyst expectations. Genmab guided to 2026 revenue of $4.3 billion to $4.5 billion, compared with consensus of approximately $4.4 billion. The range confirms continued growth but does not represent a major consensus reset. Genmab 2026 Q2 Results Presentation
Genmab A/S Company Profile
Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.
Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.
See Also
- Five stocks we like better than Genmab A/S
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
